Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics
Today's Latest Price: $13.38 USD
May 27 4:00pm Add XENE to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank XENE Stock Summary Of note is the ratio of Xenon Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 10.87% of US stocks have a lower such ratio. With a price/sales ratio of 34.65, Xenon Pharmaceuticals Inc has a higher such ratio than 95.45% of stocks in our set. Revenue growth over the past 12 months for Xenon Pharmaceuticals Inc comes in at 297.34%, a number that bests 97.79% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to Xenon Pharmaceuticals Inc are UMRX, LQDA, MCRB, KALV, and CLDX. XENE's SEC filings can be seen here. And to visit Xenon Pharmaceuticals Inc's official web site, go to www.xenon-pharma.com. XENE Price/Volume Stats
467.95M Xenon Pharmaceuticals Inc. (XENE) Company Bio
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.
XENE Latest News Stream
All News Types Corp. News Earnings New Coverage (Bullish) Product News PT Raised Stock Offering
Event/Time News Detail Loading, please wait... Latest XENE News From Around the Web
Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) just released its latest quarterly results and things are looking bullish...
It hasn't been the best quarter for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shareholders, since the share price has...
Ladies and gentlemen, thank you for standing by and welcome to the Q1 2020, Xenon Pharmaceuticals Earnings Conference Call. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer.
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BURNABY, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today…
Read More 'XENE' Stories Here
XENE Price Returns
-59.29% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 1.0382 seconds.